A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC).
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs Axitinib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors SCRI Development Innovations
- 15 Jul 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 May 2015 Status changed from active, no longer recruiting to completed according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.